Last reviewed · How we verify
CCH administration
CCH (collagenase clostridium histolyticum) is an injectable enzyme that breaks down collagen in penile plaques, reducing curvature and improving erectile function in Peyronie's disease.
CCH (collagenase clostridium histolyticum) is an injectable enzyme that breaks down collagen in penile plaques, reducing curvature and improving erectile function in Peyronie's disease. Used for Peyronie's disease with penile curvature deformity.
At a glance
| Generic name | CCH administration |
|---|---|
| Also known as | Collagenase Clostridium Histolyticum |
| Sponsor | Charitable Union for the Research and Education of Peyronie's Disease |
| Drug class | Collagenase enzyme |
| Target | Collagen I and III |
| Modality | Small molecule |
| Therapeutic area | Urology / Sexual Health |
| Phase | FDA-approved |
Mechanism of action
CCH contains two collagenase enzymes derived from Clostridium histolyticum that enzymatically degrade collagen types I and III, the primary structural components of the fibrotic plaques characteristic of Peyronie's disease. By degrading these plaques through direct enzymatic action, the drug reduces penile curvature and restores normal penile anatomy and function. The enzyme is injected directly into the plaque under ultrasound guidance.
Approved indications
- Peyronie's disease with penile curvature deformity
Common side effects
- Penile hematoma
- Penile ecchymosis
- Penile swelling
- Pain at injection site
- Penile corporal fibrosis
- Allergic reaction
Key clinical trials
- Repeated GON Injections in CCH (PHASE3)
- A Study to Assess Collagenase Clostridium Histolyticum (CCH) in the Treatment of Plantar Fasciitis (PFA) (PHASE2)
- Trial Comparing Treatment Strategies in Dupuytren's Contracture (PHASE4)
- Study of Different Interventions to Reduce Bruising Following CCH-Aaes Treatment for Cellulite of the Buttocks (PHASE2)
- Delayed Dose Collagenase Clostridium Histolyticum (CCH) Protocol for Men With Peyronie's Disease (PHASE4)
- Investigation of Surgery, Collagenase, and Restorex for the Improvement of Peyronie's (PHASE4)
- Efficacy of a Novel CCH Protocol for PD Among Prior Non-responders (PHASE4)
- A 1-year Trial to Inform About Long-term Exposure to Eptinezumab in Participants With Chronic Cluster Headache (cCH) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: